Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,578 INR | -0.32% |
|
+1.30% | +25.26% |
Jul. 05 | Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids | RE |
Jul. 02 | US DOJ drops Viatris unit Mylan from industry-wide antitrust probe | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.44 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.26% | 45.45B | - | ||
+34.85% | 24.63B | B+ | ||
+29.56% | 16.9B | - | ||
+21.32% | 14.57B | B+ | ||
+70.51% | 14.02B | B | ||
-0.05% | 6.79B | - | - | |
-10.06% | 6.61B | B+ | ||
+15.26% | 5.79B | B+ | ||
-8.87% | 5.73B | - | - | |
+10.29% | 4.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SUNPHARMA Stock
- SUNPHARMA Stock
- Ratings Sun Pharmaceutical Industries Ltd.